Form D · Other
Carmine Therapeutics, Inc.
Cambridge, MA · CIK 0001948053
Offering snapshot reported Nov 29, 2022 · SEC filing
- Reported sold
- $13.7M Offering amount: $13.7M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 24, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2022 | Initial | $13,697,828 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-466061
Source: Form D, filed Nov 29, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Elan Ezickson | Director |
| Donald Haut | Director, Executive |
| Harvey Lodish | Director |
| Lin Xiangqian | Director |
Issuer details
Industry: Other (See others in industry)
Address:
150 Cambridgepark Drive
Cambridge, MA, 02140
Cambridge, MA, 02140